1800 244 735

Helpline (02) 9874 9777

Through a Broader Lens: Looking at Non-Motor Symptoms in HD

Common depictions of HD emphasizing only its movement symptoms paint an incomplete picture of the real disease. HD causes both motor and non-motor symptoms that, together, affect the entire body. Now, scientists are using a broader lens to explore this full set of HD symptoms and determine how symptoms might be related in the disease.

Zooming Out

Although television shows and movies often depict Huntington’s disease (HD) as a straightforward motor disorder, anyone in the Huntington’s community knows that this image is a huge oversimplification. Understanding HD requires zooming out and viewing the disease through a much broader lens. In reality, HD is a systemic disease that affects many different parts of the body and aspects of life, and its non-motor symptoms can be just as devastating as their more infamous movement counterparts.

Our growing understanding of HD as a systemic disease brings new questions to the floor. What are the very first signs and symptoms of HD? How are different symptoms related? Do early HD symptoms affect later ones?

In this post, we’ll talk about new research beginning to answer these questions.

Symptom Close-Up

This new research centers on HD symptoms disrupting two important aspects of health: sleep and body weight.

Let’s start with sleep. You can tell how crucial sleep is for us humans by how much we do it: the average person spends more time sleeping than working, watching television, cooking, and cleaning combined.

People with HD, however, suffer sleep disruptions beginning early in the disease that affect both the quantity and quality of their sleep. As we’ve discussed previously, individuals with HD wake more often and sleep less soundly than people without the disease. We don’t know exactly why these sleep disruptions happen, but out-of-whack levels of a hormone called melatonin may be involved (read more about melatonin in HD here).

This sleep loss is important, because–even for healthy people–not getting enough shut eye is associated with a whole slew of physical and mental health issues. Heart attack, weight gain, cognitive problems–the risk for all of these, and many other health problems besides, grows when our sleep is disturbed.

People with HD also often experience progressive weight loss and low body weight during the course of their disease. Scientists are still investigating the cause of these symptoms, but we know already that it isn’t just that people with HD don’t eat enough. Instead, these symptoms may be a consequence of changes in energy balance and/or metabolism. Just like with sleep, though, these symptoms predispose people with HD to additional health concerns.

Based on these links, some scientists wonder if sleep and metabolism problems could exacerbate, or even trigger, other HD symptoms. For this idea to be true, these problems would need to pop up very early in the disease before other symptoms arise. However, we don’t know if this is the case (or not) because no one has ever pinpointed when (and if) sleep and metabolism problems actually begin in HD.

Framing the Question

To answer this question, a team of scientists at the University of Cambridge led by Dr Roger Barker designed a research study examining sleep and metabolism in HD.

In their study, Barker’s team gathered three groups of subjects: people without HD, people with pre-symptomatic HD (who had no motor symptoms yet), and people with early HD (who had mild motor symptoms). Because these subjects were all at different stages of health or disease, they gave the scientists an easy way to see what symptoms look like as HD progresses.

The scientists studied these subjects very thoroughly in the laboratory and in “real life” via questionnaires, movement and brain wave monitoring, blood tests, and measures of energy use. Being so thorough gave them confidence that whatever they observed would reflect what really happens in the disease.

A Picture Develops

This research revealed an interesting picture of sleep and metabolism in HD.

For sleep, deficits began during pre-symptomatic disease and were evident long before motor symptom onset. Similar to what happens in the later disease, these deficits primarily disrupted sleep continuity: people with pre-symptomatic HD woke up more often, spent more time awake in the middle of the night, and slept less soundly than their non-HD counterparts. These problems were progressive and worsened during early HD.

In contrast, similar deficits in metabolism did not occur ahead of motor symptom onset. In fact, the scientists didn’t observe any convincing metabolic differences between healthy volunteers and people with either pre-symptomatic or early HD. This finding was surprising, given the progressive weight loss/low body weight associated with HD, but it has already been confirmed by a second, completely independent study headed by Dr Thomas Warner at University College London.

Increasing the Resolution

Together, these results give us a higher-resolution image of non-motor symptoms in HD.

First, they show us that sleep disruptions are among HD’s first symptoms. Sleep disruptions begin before motor symptoms, just when early deficits in judgment, memory, and other cognitive skills are beginning to show up (more on this later).

Second, they highlight a little piece of the brain called the hypothalamus in HD. The hypothalamus is only about the size of an almond, but it plays an important role in regulating our states of sleep and wakefulness. If changes in this tiny part of the brain are responsible for sleep problems in HD, then these would be among the earliest brain changes to occur in the disease. Understanding these early changes could give us a good foundation for understanding the more widespread brain changes that occur during later HD.

Third, because the sleep deficits were easily measurable, they bring to the floor a potential new biomarker of HD onset or progression. Biomarkers are tests that measure or predict the progression of diseases like HD, and they’re important because they let us objectively describe the disease. A biomarker focused on some aspect of sleep that could be non-invasively monitored over time would be valuable tool in clinical trials and could eventually help to predict when a given individual would develop motor symptoms.

Finally, that this study did not find obvious deficits in metabolism emphasizes how important it is to test our ideas about what’s happening in HD – because sometimes we’re wrong. An explanation for low body weight based on altered metabolism was an attractive idea, but the new data simply don’t support it. Finding this out now is really good, because now we can move forward as we look for another, better explanation for body weight symptoms in HD.

A Flash of Speculation

One of the most intriguing findings from this research is that sleep deficits arise at the same time as early deficits in judgment, memory, and other cognitive skills during pre-symptomatic HD.

This finding is intriguing because we know that insufficient sleep wreaks havoc on the brain. For example, the moderate sleep deprivation caused by just 17 hours of wakefulness affects performance as much as a 0.05% blood alcohol level, and several major historical disasters (eg, the 1989 Exxon Valdez oil spill off Alaska, the Challenger space shuttle disaster, and the Chernobyl nuclear accident) have been attributed in part to human cognitive errors caused by lack of sleep. Thus, it is reasonable to speculate that early changes in sleep could directly to contribute to cognitive changes in the early stages of HD.

Though a link between cognitive problems and lack of sleep in HD is an interesting idea, we have to be careful about assuming that it’s true. To understand why, consider the following analogy. Imagine that you are studying crime in New York City and discover a relationship between petty crime and ice cream sales: whenever ice cream sales are booming, petty crime increases; whenever ice cream sales slump, petty crime decreases.

Given the clear relationship between these two events, would you claim that ice cream sales cause crime? Probably not. Instead, you’d come to the much more reasonable conclusion that some other factor affects both (for example, temperature – during the summer, rising temperatures could lead to more ice cream sales and more crime; during the winter, it’d be too cold for either).

We use the exact same reasoning when we talk about the relationship between sleep and cognitive deficits in HD. Even though these symptoms arise at the same time and track with one another, we don’t have enough information yet to know whether one symptom causes the other or if both are the result of some other factor in the disease. Teasing apart these possibilities is an important question that will require more research.

The Big Picture

We think that this is a solid research study showing that sleep deficits precede overt motor problems in HD (but that metabolism deficits don’t), and we’re eager to see this work applied to developing biomarkers and understanding early brain changes. Further, we’re intrigued by the possibility of a mechanistic link between sleep and cognition and await further work toward this end.

Overall, this study is also a really good reminder of HD’s complexity. Broadening our lens to understand this complexity and identify both when symptoms arise and how they interact is crucial for bringing the disease, and effective treatments, into focus. Finally, while we wait for effective therapies for HD, we have pretty good medications to help with sleep, which we encourage HD patients to speak with their physician about!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more